Clinical review: Probiotics in critical care

Critical Care

Volumn 16, Issue 6, 2012, Pages

  Crooks, Neil H ^a   Snaith, Catherine ^a   Webster, Deborah ^b   Gao, Fang ^c   Hawkey, Peter ^c,d  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT; SYNBIOTIC AGENT;

CRITICALLY ILL PATIENT; DRUG SAFETY; GASTROINTESTINAL TRACT; HOSPITAL INFECTION; HUMAN; IMMUNOMODULATION; INTENSIVE CARE; INTESTINE FLORA; INTESTINE MOTILITY; INTESTINE MUCOSA PERMEABILITY; PATIENT MONITORING; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; REVIEW; SAMPLE SIZE;

EID: 84868618556     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11382     Document Type: Review

References (97)

1. Alverdy JC, Laughlin RS, Wu L. Influence of the critically ill state on host- pathogen interactions within the intestine: gut-derived sepsis redefined. Crit Care Med 2003, 31:598-607. 10.1097/01.CCM.0000045576.55937.67, 12576972.
2. Bengmark S. Synbiotics to strengthen gut barrier function and reduce morbidity in critically ill patients. Clin Nutr 2004, 23:441-445. 10.1016/j.clnu.2004.01.005, 15297078.
3. MacFie J, O'Boyle C, Mitchell CJ, Buckley PM, Johnstone D, Sudworth P. Gut origin of sepsis: a prospective study investigating associations between bacterial translocation, gastric microflora, and septic morbidity. Gut 1999, 45:223-228. 10.1136/gut.45.2.223, 1727620, 10403734.
4. Hassoun HT, Kone BC, Mercer DW, Moody FG, Weisbrodt NW, Moore FA. Post-injury multiple organ failure: the role of the gut. Shock 2001, 15:1-10.
5. Sherman PM, Ossa JC, Johnson-Henry K. Unraveling mechanisms of action of probiotics. Nutr Clin Pract 2009, 24:10-14. 10.1177/0884533608329231, 19244144.
6. Guarner F, Khan AG, Garisch J, Eliakim R, Gangl A, Thomson A, et al. World gastroenterology organisation global guidelines: probiotics and prebiotics october 2011. J Clin Gastroenterol 2012, 46:468-481. 10.1097/MCG.0b013e3182549092, 22688142.
7. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr 1995, 125:1401-1412.
8. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto J-M, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180. 10.1038/nature09944, 21508958.
9. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto J-M, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010, 464:59-65. 10.1038/nature08821, 20203603.
10. Sepp E, Mikelsaar M, Salminen S. Effect of administration of Lactobacillus casei strain GG on the gastrointestinal microbiota of newborns. Microb Ecol Health Dis 1993, 6:309-314.
11. Benno Y, He F, Hosoda M, Hashimoto H, Kojima T, Yamazaki K, Iino H, Mykkanen H, Salminen S. Effect of Lactobacillus GG yoghurt on human intestinal microecology in Japanese subjects. Nutr Today 1996, 31(Suppl 1):9s-11s.
12. Fayol-Messaoudi D, Berger CN, Coconnier-Polter M-H, Liévin-Le Moal V, Servin AL. pH-, lactic acid-, and non-lactic acid-dependent activities of probiotic Lactobacilli against Salmonella enterica Serovar Typhimurium. Appl Environ Microbiol 2005, 71:6008-6013. 10.1128/AEM.71.10.6008-6013.2005, 1266002, 16204515.
13. Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999, 13:1103-1108. 10.1046/j.1365-2036.1999.00560.x, 10468688.
14. Corr SC, Li Y, Riedel CU, O'Toole PW, Hill C, Gahan CGM. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc Natl Acad Sci USA 2007, 104:7617-7621. 10.1073/pnas.0700440104, 1863472, 17456596.
15. Ng SC, Hart AL, Kamm MA, Stagg AJ, Knight SC. Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis 2009, 15:300-310. 10.1002/ibd.20602, 18626975.
16. Flynn S, van Sinderen D, Thornton GM, Holo H, Nes IF, Collins JK. Characterization of the genetic locus responsible for the production of ABP-118, a novel bacteriocin produced by the probiotic bacterium Lactobacillus salivarius subsp. salivarius UCC118. Microbiology 2002, 148:973-984.
17. Medellin-Peña MJ, Wang H, Johnson R, Anand S, Griffiths MW. Probiotics affect virulence-related gene expression in Escherichia coli O157:H7. Appl Environ Microbiol 2007, 73:4259-4267. 10.1128/AEM.00159-07, 1932779, 17496132.
18. Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 1999, 276:G941-G950.
19. Walker WA. Mechanisms of action of probiotics. Clin Infect Dis 2008, 46(Suppl 2):S87-S91. discussion S144-S151.
20. Allen SJ, Okoko B, Martinez E, Gregorio G, Dans LF. Probiotics for treating infectious diarrhoea. Cochrane Database Syst Rev 2004, 2:CD003048.
21. Gatt M, Reddy BS, MacFie J. Review article: bacterial translocation in the critically ill - evidence and methods of prevention. Aliment Pharmacol Ther 2007, 25:741-757.
22. Shimizu K, Ogura H, Hamasaki T, Goto M, Tasaki O, Asahara T, Nomoto K, Morotomi M, Matsushima A, Kuwagata Y, Sugimoto H. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci 2011, 56:1171-1177. 10.1007/s10620-010-1418-8, 3059822, 20931284.
23. Inglis TJJ, Sherratt MJ, Sproat LJ, Hawkey PM, Gibson JS. Gastroduodenal dysfunction and bacterial colonisation of the ventilated lung. The Lancet 1993, 341:911-913.
24. McNaught CE, Woodcock NP, MacFie J, Mitchell CJ. A prospective randomised study of the probiotic Lactobacillus plantarum 299V on indices of gut barrier function in elective surgical patients. Gut 2002, 51:827-831. 10.1136/gut.51.6.827, 1773461, 12427785.
25. Anderson ADG, McNaught CE, Jain PK, MacFie J. Randomised clinical trial of synbiotic therapy in elective surgical patients. Gut 2004, 53:241-245. 10.1136/gut.2003.024620, 1774935, 14724157.
26. Reddy BS, Macfie J, Gatt M, Larsen CN, Jensen SS, Leser TD. Randomized clinical trial of effect of synbiotics, neomycin and mechanical bowel preparation on intestinal barrier function in patients undergoing colectomy. Br J Surg 2007, 94:546-554. 10.1002/bjs.5705, 17443852.
27. Nomura T, Tsuchiya Y, Nashimoto A, Yabusaki H, Takii Y, Nakagawa S, Sato N, Kanbayashi C, Tanaka O. Probiotics reduce infectious complications after pancreaticoduodenectomy. Hepatogastroenterology 2007, 54:661-663.
28. Rayes N, Seehofer D, Theruvath T, Mogl M, Langrehr JM, Nüssler NC, Bengmark S, Neuhaus P. Effect of enteral nutrition and synbiotics on bacterial infection rates after pylorus-preserving pancreatoduodenectomy: a randomized, double-blind trial. Ann Surg 2007, 246:36-41. 10.1097/01.sla.0000259442.78947.19, 1899208, 17592288.
29. Kanazawa H, Nagino M, Kamiya S, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch Surg 2005, 390:104-113. 10.1007/s00423-004-0536-1, 15711820.
30. Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, Nomoto K, Nimura Y. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 2006, 244:706-714. 10.1097/01.sla.0000219039.20924.88, 1856608, 17060763.
31. Rayes N, Seehofer D, Hansen S, Boucsein K, Müller AR, Serke S, Bengmark S, Neuhaus P. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation 2002, 74:123-127. 10.1097/00007890-200207150-00021, 12134110.
32. Rayes N, Seehofer D, Theruvath T, Schiller RA, Langrehr JM, Jonas S, Bengmark S, Neuhaus P. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantation - a randomized, double-blind trial. Am J Transplant 2005, 5:125-130. 10.1111/j.1600-6143.2004.00649.x, 15636620.
33. Oláh A, Belágyi T, Issekutz A, Gamal ME, Bengmark S. Randomized clinical trial of specific lactobacillus and fibre supplement to early enteral nutrition in patients with acute pancreatitis. Br J Surg 2002, 89:1103-1107. 10.1046/j.1365-2168.2002.02189.x, 12190674.
34. Oláh A, Belágyi T, Pótó L, Romics L, Bengmark S. Synbiotic control of inflammation and infection in severe acute pancreatitis: a prospective, randomized, double blind study. Hepatogastroenterology 2007, 54:590-594.
35. Besselink MGH, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJM, Rosman C, Ploeg RJ, Brink MA, Schaapherder AFM, Dejong CHC, Wahab PJ, van Laarhoven CJHM, van der Harst E, van Eijck CHJ, Cuesta MA, Akkermans LMA, Gooszen HG. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:651-659. 10.1016/S0140-6736(08)60207-X, 18279948.
36. Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995, 274:639-644. 10.1001/jama.1995.03530080055041, 7637145.
37. Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319.
38. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med 2010, 182:1058-1064. 10.1164/rccm.200912-1853OC, 2970846, 20522788.
39. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005, 171:388-416.
40. Vincent J-L, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall J-R, Payen D. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006, 34:344-353. 10.1097/01.CCM.0000194725.48928.3A, 16424713.
41. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005, 128:3854-3862. 10.1378/chest.128.6.3854, 16354854.
42. Liberati A, D'Amico R, Pifferi S, Torri V, Brazzi L, Parmelli E. Antibiotic prophylaxis to reduce respiratory tract infections and mortality in adults receiving intensive care. Cochrane Database Syst Rev 2009, 4:CD000022.
43. de Smet AMGA, Kluytmans JAJW, Cooper BS, Mascini EM, Benus RFJ, van der Werf TS, van der Hoeven JG, Pickkers P, Bogaers-Hofman D, van der Meer NJM, Bernards AT, Kuijper EJ, Joore JCA, Leverstein-van Hall MA, Bindels AJGH, Jansz AR, Wesselink RMJ, de Jongh BM, Dennesen PJW, van Asselt GJ, te Velde LF, Frenay IHME, Kaasjager K, Bosch FH, van Iterson M, Thijsen SFT, Kluge GH, Pauw W, de Vries JW, Kaan JA, et al. Decontamination of the digestive tract and oropharynx in ICU patients. N Engl J Med 2009, 360:20-31. 10.1056/NEJMoa0800394, 19118302.
44. Oostdijk EAN, de Smet AMGA, Blok HEM, Thieme Groen ES, van Asselt GJ, Benus RFJ, Bernards SAT, Frénay IHME, Jansz AR, de Jongh BM, Kaan JA, Leverstein-van Hall MA, Mascini EM, Pauw W, Sturm PDJ, Thijsen SFT, Kluytmans JAJW, Bonten MJM. Ecological effects of selective decontamination on resistant gram-negative bacterial colonization. Am J Respir Crit Care Med 2010, 181:452-457. 10.1164/rccm.200908-1210OC, 19965807.
45. García-San Vicente B, Canut A, Labora A, Otazua M, Corral E. [Selective decontamination of the digestive tract: repercussions on microbiology laboratory workload and costs, and antibiotic resistance trends]. Enferm Infecc Microbiol Clin 2010, 28:75-81. 10.1016/j.eimc.2009.03.005, 19632746.
46. Al Naiemi N, Heddema ER, Bart A, de Jonge E, Vandenbroucke-Grauls CM, Savelkoul PHM, Duim B. Emergence of multidrug-resistant Gram-negative bacteria during selective decontamination of the digestive tract on an intensive care unit. J Antimicrob Chemother 2006, 58:853-856. 10.1093/jac/dkl316, 16891326.
47. Kotzampassi K, Giamarellos-Bourboulis EJ, Voudouris A, Kazamias P, Eleftheriadis E. Benefits of a synbiotic formula (Synbiotic 2000Forte) in critically Ill trauma patients: early results of a randomized controlled trial. World J Surg 2006, 30:1848-1855. 10.1007/s00268-005-0653-1, 16983476.
48. Spindler-Vesel A, Bengmark S, Vovk I, Cerovic O, Kompan L. Synbiotics, prebiotics, glutamine, or peptide in early enteral nutrition: a randomized study in trauma patients. JPEN J Parenter Enteral Nutr 2007, 31:119-126. 10.1177/0148607107031002119, 17308252.
49. Forestier C, Guelon D, Cluytens V, Gillart T, Sirot J, De Champs C. Oral probiotic and prevention of Pseudomonas aeruginosa infections: a randomized, double-blind, placebo-controlled pilot study in intensive care unit patients. Crit Care 2008, 12:R69. 10.1186/cc6907, 2481460, 18489775.
50. Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic Lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care 2008, 12:R136. 10.1186/cc7109, 2646346, 18990201.
51. Knight DJW, Gardiner D, Banks A, Snape SE, Weston VC, Bengmark S, Girling KJ. Effect of synbiotic therapy on the incidence of ventilator associated pneumonia in critically ill patients: a randomised, double-blind, placebocontrolled trial. Intensive Care Med 2009, 35:854-861. 10.1007/s00134-008-1368-1, 19083199.
52. Oudhuis GJ, Bergmans DC, Dormans T, Zwaveling J-H, Kessels A, Prins MH, Stobberingh EE, Verbon A. Probiotics versus antibiotic decontamination of the digestive tract: infection and mortality. Intensive Care Med 2011, 37:110-117. 10.1007/s00134-010-2002-6, 3020315, 20721536.
53. Barraud D, Blard C, Hein F, Marçon O, Cravoisy A, Nace L, Alla F, Bollaert P-E, Gibot S. Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med 2010, 36:1540-1547. 10.1007/s00134-010-1927-0, 20502866.
54. Watkinson PJ, Barber VS, Dark P, Young JD. The use of pre- pro- and synbiotics in adult intensive care unit patients: systematic review. Clin Nutr 2007, 26:182-192. 10.1016/j.clnu.2006.07.010, 17011083.
55. Siempos II, Ntaidou TK, Falagas ME. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med 2010, 38:954-962. 10.1097/CCM.0b013e3181c8fe4b, 20016381.
56. Knight D, Ala'Aldeen D, Bengmark S, Girling K. The effect of probiotics on gastrointestinal flora in the critically ill. Br J Anaesth 2004, 92:307-308.
57. Tuomola E, Crittenden R, Playne M, Isolauri E, Salminen S. Quality assurance criteria for probiotic bacteria. Am J Clin Nutr 2001, 73:393S-398S.
58. Clements ML, Levine MM, Ristaino PA, Daya VE, Hughes TP. Exogenous lactobacilli fed to man - their fate and ability to prevent diarrheal disease. Prog Food Nutr Sci 1983, 7:29-37.
59. Isakow W, Morrow LE, Kollef MH. Probiotics for preventing and treating nosocomial infections: review of current evidence and recommendations. Chest 2007, 132:286-294. 10.1378/chest.06-2156, 17625089.
60. Salminen MK, Rautelin H, Tynkkynen S, Poussa T, Saxelin M, Valtonen V, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis 2004, 38:62-69. 10.1086/380455, 14679449.
61. Salminen MK, Tynkkynen S, Rautelin H, Saxelin M, Vaara M, Ruutu P, et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis 2002, 35:1155-1160. 10.1086/342912, 12410474.
62. Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, Koskela M. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999, 28:1159-1160. 10.1086/514766, 10452653.
63. Mackay A, Taylor M, Kibbler C, Hamilton-Miller J. Lactobacillus endocarditis caused by a probiotic organism. Clin Microbiol Infect 1999, 5:290-292. 10.1111/j.1469-0691.1999.tb00144.x, 11856270.
64. Kunz A, Noel J, Fairchok M. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 2004, 38:457-458. 10.1097/00005176-200404000-00017, 15085028.
65. Land M, Rouster-Stecens K, Woods C, Cannon M, Cnota J, Shetty A. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005, 115:178-181.
66. Abgrall S, Joly V, Derkinderen P, Decré D, Carbon C, Yeni P. Lactobacillus casei infection in an AIDS patient. Eur J Clin Microbiol Infect Dis 1997, 16:180-182. 10.1007/BF01709485, 9105853.
67. Jones SD, Fullerton DA, Zamora MR, Badesch DB, Campbell DN, Grover FL. Transmission of Lactobacillus pneumonia by a transplanted lung. Ann Thorac Surg 1994, 58:887-889. 10.1016/0003-4975(94)90779-X, 7944727.
68. Patel R, Cockerill FR, Porayko MK, Osmon DR, Ilstrup DM, Keating MR. Lactobacillemia in liver transplant patients. Clin Infect Dis 1994, 18:207-212. 10.1093/clinids/18.2.207, 8161628.
69. Saxelin M, Chuang NH, Chassy B, Rautelin H, Mäkelä PH, Salminen S, Gorbach SL. Lactobacilli and bacteremia in southern Finland, 1989-1992. Clin Infect Dis 1996, 22:564-566. 10.1093/clinids/22.3.564, 8852980.
70. Guenther K, Straube E, Pfister W, Guenther A, Huebler A. Severe sepsis after probiotic treatment with Escherichia coli NISSLE 1917. Pediatr Infect Dis J 2010, 29:188-189.
71. Timmerman HM, Niers LEM, Ridwan BU, Koning CJM, Mulder L, Akkermans LMA, Rombouts FM, Rijkers GT. Design of a multispecies probiotic mixture to prevent infectious complications in critically ill patients. Clin Nutr 2007, 26:450-459. 10.1016/j.clnu.2007.04.008, 17544549.
72. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009, 64(Suppl 1):i3-i10.
73. Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar AV, Maharjan S, Mushtaq S, Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M, Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore DM, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010, 10:597-602. 10.1016/S1473-3099(10)70143-2, 2933358, 20705517.
74. Adlerberth I, Ahrne S, Johansson ML, Molin G, Hanson LA, Wold AE. A mannose-specific adherence mechanism in Lactobacillus plantarum conferring binding to the human colonic cell line HT-29. Appl Environ Microbiol 1996, 62:2244-2251. 168005, 8779562.
75. Forestier C, De Champs C, Vatoux C, Joly B. Probiotic activities of Lactobacillus casei rhamnosus: in vitro adherence to intestinal cells and antimicrobial properties. Res Microbiol 2001, 152:167-173. 10.1016/S0923-2508(01)01188-3, 11316370.
76. Otte J-M, Podolsky DK. Functional modulation of enterocytes by Grampositive and Gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 2004, 286:G613-G626. 10.1152/ajpgi.00341.2003, 15010363.
77. Wehkamp J, Harder J, Wehkamp K, Wehkamp-von Meissner B, Schlee M, Enders C, Sonnenborn U, Nuding S, Bengmark S, Fellermann K, Schröder JM, Stange EF. NF-kappaB- and AP-1-mediated induction of human beta defensin-2 in intestinal epithelial cells by Escherichia coli Nissle 1917: a novel effect of a probiotic bacterium. Infect Immun 2004, 72:5750-5758. 10.1128/IAI.72.10.5750-5758.2004, 517557, 15385474.
78. Resta-Lenert S, Barrett KE. Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003, 52:988-997. 10.1136/gut.52.7.988, 1773702, 12801956.
79. Meddings J. The significance of the gut barrier in disease. Gut 2008, 57:438-440.
80. Sherman PM, Johnson-Henry KC, Yeung HP, Ngo PSC, Goulet J, Tompkins TA. Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun 2005, 73:5183-5188. 10.1128/IAI.73.8.5183-5188.2005, 1201237, 16041036.
81. Yan F, Polk DB. Probiotic bacterium prevents cytokine-induced apoptosis in intestinal epithelial cells. J Biol Chem 2002, 277:50959-50965. 10.1074/jbc.M207050200, 12393915.
82. Ichikawa H, Kuroiwa T, Inagaki A, Shineha R, Nishihira T, Satomi S, Sakata T. Probiotic bacteria stimulate gut epithelial cell proliferation in rat. Dig Dis Sci 1999, 44:2119-2123. 10.1023/A:1026647024077, 10548366.
83. de Champs C, Maroncle N, Balestrino D, Rich C, Forestier C. Persistence of colonization of intestinal mucosa by a probiotic strain, Lactobacillus casei subsp. rhamnosus Lcr35, after oral consumption. J Clin Microbiol 2003, 41:1270-1273. 10.1128/JCM.41.3.1270-1273.2003, 150315, 12624065.
84. Reissbrodt R, Hammes WP, dal Bello F, Prager R, Fruth A, Hantke K, Rakin A, Starcic-Erjavec M, Williams PH. Inhibition of growth of Shiga toxinproducing Escherichia coli by nonpathogenic Escherichia coli. FEMS Microbiol Lett 2009, 290:62-69. 10.1111/j.1574-6968.2008.01405.x, 19016876.
85. Shi HN, Walker A. Bacterial colonization and the development of intestinal defences. Can J Gastroenterol 2004, 18:493-500.
86. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001, 2:675-680. 10.1038/90609, 11477402.
87. Ulisse S, Gionchetti P, D'Alò S, Russo FP, Pesce I, Ricci G, Rizzello F, Helwig U, Cifone MG, Campieri M, De Simone C. Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol 2001, 96:2691-2699. 10.1111/j.1572-0241.2001.04139.x, 11569697.
88. Pathmakanthan S, Li CKF, Cowie J, Hawkey CJ. Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 2004, 19:166-173. 10.1111/j.1440-1746.2004.03181.x, 14731126.
89. Borruel N, Carol M, Casellas F, Antolín M, de Lara F, Espín E, Naval J, Guarner F, Malagelada JR. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002, 51:659-664. 10.1136/gut.51.5.659, 1773447, 12377803.
90. Arribas B, Rodríguez-Cabezas ME, Camuesco D, Comalada M, Bailón E, Utrilla P, Nieto A, Concha A, Zarzuelo A, Gálvez J. A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol 2009, 157:1024-1033. 10.1111/j.1476-5381.2009.00270.x, 2737661, 19486007.
91. Kaila M, Isolauri E, Soppi E, Virtanen E, Laine S, Arvilommi H. Enhancement of the circulating antibody secreting cell response in human diarrhea by a human Lactobacillus strain. Pediatr Res 1992, 32:141-144. 10.1203/00006450-199208000-00002, 1324462.
92. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991, 88:90-97.
93. Teitelbaum JE, Walker WA. Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Annu Rev Nutr 2002, 22:107-138. 10.1146/annurev.nutr.22.110901.145412, 12055340.
94. Shida K, Nanno M, Nagata S. Flexible cytokine production by macrophages and T cells in response to probiotic bacteria: a possible mechanism by which probiotics exert multifunctional immune regulatory activities. Gut Microbes 2011, 2:109-114. 10.4161/gmic.2.2.15661, 21637028.
95. Takeda K, Suzuki T, Shimada S-I, Shida K, Nanno M, Okumura K. Interleukin-12 is involved in the enhancement of human natural killer cell activity by Lactobacillus casei Shirota. Clin Exp Immunol 2006, 146:109-115. 10.1111/j.1365-2249.2006.03165.x, 1809741, 16968405.
96. Hatcher GE, Lambrecht RS. Augmentation of macrophage phagocytic activity by cell-free extracts of selected lactic acid-producing bacteria. J Dairy Sci 1993, 76:2485-2492. 10.3168/jds.S0022-0302(93)77583-9, 8227651.
97. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Schulze J. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623. 10.1136/gut.2003.037747, 1774300, 15479682.